HCC screening in viral hepatitis

Why Screen? - The Hepatitis-HCC Link

• Chronic viral hepatitis (HBV & HCV) is the leading driver of Hepatocellular Carcinoma (HCC).
• Mechanism: Persistent inflammation → hepatocyte regeneration → fibrosis → cirrhosis.
• HBV: Directly oncogenic; viral DNA integrates into the host genome, causing HCC even without cirrhosis.
• HCV: Indirectly oncogenic; HCC risk is primarily mediated through chronic inflammation leading to cirrhosis.
• Goal: Early detection via screening improves survival.

⭐ Up to 50% of HBV-related HCC cases occur in patients without cirrhosis, making screening crucial for all chronic carriers, not just those with cirrhosis.

Screening Indications - The Cirrhosis Club

• All patients with established cirrhosis are candidates for HCC screening, regardless of etiology (HCV, HBV, NAFLD, alcohol).

  • Screening consists of an abdominal ultrasound every 6 months.
  • Alpha-fetoprotein (AFP) may be used as an adjunct, but has limitations in sensitivity and specificity.

• Certain high-risk groups with chronic Hepatitis B without cirrhosis also warrant screening:

  • Asian males > 40 years old
  • Asian females > 50 years old
  • Individuals of African descent
  • Those with a first-degree relative with HCC

⭐ Achieving a sustained virologic response (SVR) in Hepatitis C reduces HCC risk by ~75%. However, the risk is not eliminated. Patients with pre-existing cirrhosis MUST continue HCC surveillance even after a curative course of direct-acting antivirals (DAAs).

The Screening Playbook - Scan & See

• Primary Tool: Abdominal ultrasound (US) of the liver every 6 months.
• Adjunct Biomarker: Alpha-fetoprotein (AFP).
  • A rising trend is more significant than a single value.
• Goal: Detect small, early-stage tumors for curative therapy.

⭐ While AFP has limitations, a value >20 ng/mL should prompt further imaging regardless of ultrasound findings.

Positive Screen? - The Follow-Up Flow

• For patients with cirrhosis or chronic hepatitis B, surveillance with ultrasound (US) is key.

⭐ Classic imaging features of HCC on multiphasic CT/MRI are arterial phase hyperenhancement (APHE) and venous/delayed phase washout. These findings are highly specific (LI-RADS 5) and can establish a diagnosis without biopsy.

High‑Yield Points - ⚡ Biggest Takeaways

• All patients with cirrhosis, regardless of etiology, require HCC screening.
• Patients with chronic hepatitis B may require screening even without cirrhosis.
• The standard screening modality is abdominal ultrasound every 6 months.
• Alpha-fetoprotein (AFP) has low sensitivity and is not recommended for standalone screening.
• The primary goal is early detection of hepatocellular carcinoma to improve outcomes.
• Cirrhosis remains the single most important risk factor for HCC development.